Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
PBYI•Q2 revenue rises on higher NERLYNX demand
Puma Biotechnology said its second-quarter product revenue rose year over year on higher demand for NERLYNX. The U.S. cancer drug maker also said adjusted earnings per share increased year over year.
The company said higher operating costs were mainly due to increased clinical trial expense for alisertib. Management attributed the improved results to commercial execution and progress in clinical development.
Second-quarter results and analyst context
| Metric | Actual | Consensus Estimate |
|---|---|---|
| Q2 Total Revenue | $56.50 million | |
| Q2 Adjusted EPS | $0.19 | $0.04 (1 analyst) |
| Q2 EPS | $0.16 | |
| Q2 Adjusted Net Income | $10.10 million | $1.90 million (1 analyst) |
| Q2 Net Income | $8.20 million |
The one available analyst rating on the shares is hold. The average consensus recommendation for the pharmaceuticals peer group is buy. Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 37.4% below its August 5 closing price of $7.99. The stock recently traded at 33 times the next 12-month earnings versus a P/E of 16 three months ago.
